Airway inflammation in COPD: Friend or foe?

American Journal of Respiratory and Critical Care Medicine

Volumn 176, Issue 5, 2007, Pages 425-426

  Brusasco, Vito ^a   Crimi, Emanuele ^a   Pellegrino, Riccardo ^b  

^a UNIVERSITY OF GENOA   (Italy)

^b S CROCE E CARLE HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ABSENTEEISM; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL FEATURE; EDITORIAL; HOSPITALIZATION COST; HUMAN; IMMUNE RESPONSE; INFLAMMATION; MORBIDITY; MORTALITY; MUCUS SECRETION; PREVALENCE; PRIORITY JOURNAL; RESPIRATORY TRACT DISEASE;

ANTI-INFLAMMATORY AGENTS; DISEASE PROGRESSION; HUMANS; IMMUNITY; INFLAMMATION; MUCUS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 34548462668     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.200706-820ED     Document Type: Editorial

References (16)

1. Mac Nee W. Aetiology and pathogenesis of chronic obstructive pulmonary disease. In: Gibson GJ, Geddes DM, Costabel U, Sterk PJ, Corrin B, editors. Respiratory medicine, 3rd ed. Vol. II. Oxford, UK: Saunders; 2003. pp. 1121-1140.
2. Calverley P, Pauwels R, Vestbo J, Jones P, Pride N, Gulsvik A, Anderson J. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomized controlled trial. Lancet 2003;361:449-456.
3. Calverley PM, Boonswat W, Cseke Z, Zhong N, Peterson S, Olsson H. Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. Eur Respir J 2003;22:912-919.
4. Kardos P, Wencker M, Glaab T, Vogelmeier C. Impact of salmeterol/fluticasone propionate versus salmeterol on exacerbations in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007;175:144-149.
5. Calverley PMA, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones P, Yates BS, Vestbo J, for the TORCH Investigators. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007;356:775-789.
6. Sin DD, Man SF. Why are patients with chronic obstructive pulmonary disease at increased risk of cardiovascular disease? The potential role of systemic inflammation in chronic obstructive pulmonary disease. Circulation 2003;107:1514-1519.
7. Hogg JC, Chu FSF, Tan WC, Sin DD, Patel SA, Paré PD, Martinez FJ, Rogers RM, Make BJ, Criner GJ, et al. Survival after lung volume reduction in chronic obstructive pulmonary disease: insights from small airway pathology. Am J Respir Crit Care Med 2007;176:454-459.
8. Fletcher C, Peto R. The natural history of chronic airflow obstruction. BMJ 1977;1:1645-1648.
9. Vestbo J, Lange P. Can GOLD stage 0 provide information of prognostic value in chronic obstructive pulmonary disease? Am J Respir Crit Care Med 2002;166:329-332.
10. De Marco R, Accordini S, Cerveri I, Corsico A, Antó JM, Künzli N, Janson C, Sunyer J, Jarvis D, Chinn S, et al. Incidence of chronic obstructive pulmonary disease in a cohort of young adults according to the presence of chronic cough and phlegm. Am J Respir Crit Care Med 2007;175:32-39.
11. Randell SH. Airway epithelial stem cells and the pathophysiology of chronic obstructive pulmonary disease. Proc Am Thorac Soc 2006;3:718-725.
12. Rodriguez J, Niederman MS, Fein AM, Pai PB. Nonresolving pneumonia in steroid-treated patients with obstructive lung disease. Am J Med 1992;93:29-34.
13. Ernst P, Gonzalez AV, Brassard P, Suissa S. Inhaled corticosteroid use in COPD and the risk of hospitalization for pneumonia. Am J Respir Crit Care Med 2007;176:162-166.
14. Yang IA, Fong KM, Sim EHA, Black PN, Lasserson TJ. Inhaled corticosteroids for stable chronic obstructive pulmonary disease [review]. Cochrane Database Syst Rev 2007;18:CD002991.
15. Rutgers SR, Postma DS, ten Hacken NH, Kauffman HF, van Der Mark TW, Koeter GH, Timens W. Ongoing airway inflammation in patients with COPD who do not currently smoke. Thorax 2000;55:12-18.
16. Churg A, Tai H, Coulthard T, Wand R, Wright JL. Cigarette smoke drives small airway remodeling by induction of growth factors in the airway wall. Am J Respir Crit Care Med 2006;174:1327-1334.